IFN-I signaling in cDCs, including that induced by STING agonists, upregulates the expression of IL-15/IL-15Rα by cDCs, which is thought to augment anti-tumor immunity via the activation of cDCs, CD8+ T cells, and natural killer (NK) cells [27,28,29]. The gene discussed is IL15; the disease is neoplasm.